BioCentury | Mar 5, 2021
Deals

March 4 Quick Takes: Crossovers pour into Amunix’s $117M B round; plus funding for atai, BlossomHill, OnKure, Exscientia, CorVista, Blue Note and Geneos and deals for Takeda-Enzyre, ConserV-eTheRNA

...series C round at $100 million. The U.K.-based company has multiple partnerships with pharmas, including Dainippon Sumitomo Pharma Co. Ltd....
BioCentury | Jan 31, 2020
Clinical News

AI strengthens grip on low hanging fruit with Exscientia, Dainippon Sumitomo trial start

...Exscientia and Dainippon Sumitomo’s trial start for a compound accelerated through preclinical development via AI suggests the...
...in drug development by accessing insights humans can’t find on their own. Exscientia Ltd. and Dainippon Sumitomo Pharma Co. Ltd....
...the basis for its chemistry platform in a 2012 study in Nature . Exscientia and Dainippon Sumitomo...
BioCentury | Jun 29, 2015
Company News

Dainippon Sumitomo, Takeda deal

...will revert back to Sumitomo Dainippon on Jan. 31, 2016 (see BioCentury, May 16, 2011). Dainippon Sumitomo Pharma Co. Ltd....
BioCentury | Dec 8, 2014
Company News

SanBio, Dainippon Sumitomo deal

...see BioCentury, Oct. 11, 2010 & March 10, 2014). SanBio Co. Ltd. , Tokyo, Japan Dainippon Sumitomo Pharma Co. Ltd....
BioCentury | Nov 3, 2014
Company News

GlaxoSmithKline, Dainippon Sumitomo deal

...selective serotonin reuptake inhibitor (SSRI) (see BioCentury, Jan. 30, 2012). GlaxoSmithKline plc (LSE:GSK;NYSE:GSK), London, U.K. Dainippon Sumitomo Pharma Co. Ltd....
BioCentury | Jun 23, 2014
Clinical News

Obeticholic acid regulatory update

...product has Orphan Drug designation in the U.S. and EU to treat PBC and PSC. Dainippon Sumitomo Pharma Co. Ltd....
BioCentury | Jun 16, 2014
Clinical News

Vatiquinone regulatory update

...EPI-743 in Japan (see BioCentury, April 1, 2013). Edison Pharmaceuticals Inc. , Mountain View, Calif. Dainippon Sumitomo Pharma Co. Ltd....
BioCentury | Jun 12, 2014
Cover Story

Nav-i-gating antibodies for pain

...Description Phase of development Convergence Pharmaceuticals Ltd. CNV1014802 Small molecule, state-dependent Nav1.7 inhibitor Phase II Dainippon Sumitomo Pharma Co. Ltd....
BioCentury | Jun 2, 2014
Company News

Daiichi Sankyo, Dainippon Sumitomo deal

...a partial agonist of serotonin (5-HT1A) receptor . Daiichi Sankyo Co. Ltd. (Tokyo:4568), Tokyo, Japan Dainippon Sumitomo Pharma Co. Ltd....
BioCentury | Jun 2, 2014
Clinical News

BBI608: Phase III discontinued

...gained BBI608 through its 2012 acquisition of Boston Biomedical Inc. (see BioCentury, April 30, 2012). Dainippon Sumitomo Pharma Co. Ltd....
Items per page:
1 - 10 of 417
BioCentury | Mar 5, 2021
Deals

March 4 Quick Takes: Crossovers pour into Amunix’s $117M B round; plus funding for atai, BlossomHill, OnKure, Exscientia, CorVista, Blue Note and Geneos and deals for Takeda-Enzyre, ConserV-eTheRNA

...series C round at $100 million. The U.K.-based company has multiple partnerships with pharmas, including Dainippon Sumitomo Pharma Co. Ltd....
BioCentury | Jan 31, 2020
Clinical News

AI strengthens grip on low hanging fruit with Exscientia, Dainippon Sumitomo trial start

...Exscientia and Dainippon Sumitomo’s trial start for a compound accelerated through preclinical development via AI suggests the...
...in drug development by accessing insights humans can’t find on their own. Exscientia Ltd. and Dainippon Sumitomo Pharma Co. Ltd....
...the basis for its chemistry platform in a 2012 study in Nature . Exscientia and Dainippon Sumitomo...
BioCentury | Jun 29, 2015
Company News

Dainippon Sumitomo, Takeda deal

...will revert back to Sumitomo Dainippon on Jan. 31, 2016 (see BioCentury, May 16, 2011). Dainippon Sumitomo Pharma Co. Ltd....
BioCentury | Dec 8, 2014
Company News

SanBio, Dainippon Sumitomo deal

...see BioCentury, Oct. 11, 2010 & March 10, 2014). SanBio Co. Ltd. , Tokyo, Japan Dainippon Sumitomo Pharma Co. Ltd....
BioCentury | Nov 3, 2014
Company News

GlaxoSmithKline, Dainippon Sumitomo deal

...selective serotonin reuptake inhibitor (SSRI) (see BioCentury, Jan. 30, 2012). GlaxoSmithKline plc (LSE:GSK;NYSE:GSK), London, U.K. Dainippon Sumitomo Pharma Co. Ltd....
BioCentury | Jun 23, 2014
Clinical News

Obeticholic acid regulatory update

...product has Orphan Drug designation in the U.S. and EU to treat PBC and PSC. Dainippon Sumitomo Pharma Co. Ltd....
BioCentury | Jun 16, 2014
Clinical News

Vatiquinone regulatory update

...EPI-743 in Japan (see BioCentury, April 1, 2013). Edison Pharmaceuticals Inc. , Mountain View, Calif. Dainippon Sumitomo Pharma Co. Ltd....
BioCentury | Jun 12, 2014
Cover Story

Nav-i-gating antibodies for pain

...Description Phase of development Convergence Pharmaceuticals Ltd. CNV1014802 Small molecule, state-dependent Nav1.7 inhibitor Phase II Dainippon Sumitomo Pharma Co. Ltd....
BioCentury | Jun 2, 2014
Company News

Daiichi Sankyo, Dainippon Sumitomo deal

...a partial agonist of serotonin (5-HT1A) receptor . Daiichi Sankyo Co. Ltd. (Tokyo:4568), Tokyo, Japan Dainippon Sumitomo Pharma Co. Ltd....
BioCentury | Jun 2, 2014
Clinical News

BBI608: Phase III discontinued

...gained BBI608 through its 2012 acquisition of Boston Biomedical Inc. (see BioCentury, April 30, 2012). Dainippon Sumitomo Pharma Co. Ltd....
Items per page:
1 - 10 of 417